Today: 3 March 2026
Subscribe

Mateusz Kaczmarek

A technology and finance expert writing for TS2.tech. He analyzes developments in satellites, telecommunications, and artificial intelligence, with a focus on their impact on global markets. Author of industry reports and market commentary, often cited in tech and business media. Passionate about innovation and the digital economy.

IBM Stock Rockets 28%: AI Boom, Quantum Breakthroughs & Big Deals Spark Rally

IBM Stock Rockets 28%: AI Boom, Quantum Breakthroughs & Big Deals Spark Rally

IBM closed at $281.28 on Oct. 17, up 28% year-to-date and near multi-year highs. The company announced new AI partnerships with Bharti Airtel, AMD, and Anthropic, and agreed to acquire SAP consultant Cognitus. IBM will report Q3 results on Oct. 22; analysts expect EPS around $3.00 and see limited upside unless AI/cloud growth accelerates. The stock yields 2.3% with a 45x P/E ratio.
18 October 2025
···
Psychedelic Biotech Rally: Atai Life Sciences Stock Soars 18% on FDA Breakthrough and $130M Fundraise

Psychedelic Biotech Rally: Atai Life Sciences Stock Soars 18% on FDA Breakthrough and $130M Fundraise

Atai Life Sciences shares surged 18% to close near $6.45 on Oct. 17, 2025, after the FDA granted Breakthrough Therapy status to its experimental depression nasal spray BPL-003. The company raised $130 million in a public offering at $5.48 per share. Analysts issued strong Buy ratings with targets up to $15. ARK Invest disclosed buying about 250,000 shares.
18 October 2025
·
Cisco Stock Surges Near 52-Week High on AI Momentum – What’s Next for CSCO?

Cisco Stock Surges Near 52-Week High on AI Momentum – What’s Next for CSCO?

Cisco Systems shares traded near $69–$70 on Oct. 17, 2025, close to a 52-week high and up about 30% over 12 months. The company reported Q4 earnings of $0.99 per share on $14.67 billion revenue, beating forecasts, and guided for 5–6% revenue growth in FY2026. Cisco launched new AI-focused products in October, with early orders from Microsoft and Alibaba. Market cap stands at roughly $270 billion.
18 October 2025
···
New Era Energy (NUAI) Stock Skyrockets on AI Data Center Pivot – Can the Rally Last?

New Era Energy (NUAI) Stock Skyrockets on AI Data Center Pivot – Can the Rally Last?

New Era Energy & Digital (NASDAQ: NUAI) closed at $4.55 on Oct. 17, up 44% for the day and 186% in two weeks, after announcing progress on its Texas AI data center project. The company regained Nasdaq compliance, ended plans for a new share sale, and now claims to be sufficiently funded. Market cap stands near $129 million. New Era remains pre-revenue, with heavy trading volume and ongoing volatility.
18 October 2025
···
MindMed Stock Rockets on Breakthrough LSD Anxiety Data – Analysts Eye 100% Upside

MindMed Stock Rockets on Breakthrough LSD Anxiety Data – Analysts Eye 100% Upside

MindMed shares hit a 52-week high of $13.09 on Oct. 14, up 68% year-to-date, after its LSD-derived drug MM120 showed 48% remission in a Phase 2b anxiety trial and received FDA Breakthrough Therapy status. The company holds $237.9 million in cash and is running three Phase 3 studies, with topline results due in 2026. Most analysts rate MNMD a “Moderate Buy” with an average 12-month target near $28.
18 October 2025
·
Virgin Galactic (SPCE) Stock Rockets 40% Then Reverses – What’s Fueling the Space Tourism Frenzy?

Virgin Galactic (SPCE) Stock Rockets 40% Then Reverses – What’s Fueling the Space Tourism Frenzy?

Virgin Galactic shares fell 7.9% to $4.08 on Oct. 18 after spiking over 40% earlier in the month, driven by heavy trading and high short interest. Q2 2025 revenue dropped to $0.4 million, with a net loss of $67 million. The company holds $508 million in cash, targeting late 2026 for its new Delta Class spaceplane’s first flight. Wall Street consensus is Neutral, with price targets recently cut to $2–$2.50 by some analysts.
18 October 2025
··
Sellas Life Sciences (SLS) Stock Rallies on Promising Leukemia Data – Analysts Eye Triple-Digit Upside

Sellas Life Sciences (SLS) Stock Rallies on Promising Leukemia Data – Analysts Eye Triple-Digit Upside

Sellas Life Sciences (NASDAQ:SLS) closed near $2.14 on Oct. 17, up about 100% year-to-date, with trading volatility and a 761% surge in call options on Oct. 14. Its GPS immunotherapy remains in Phase 3, while SLS009 showed strong preclinical results and a 44% response rate in Phase 2 AML data. Sellas raised $23.6M in September and had $25.3M cash at June 30. Analyst targets range from $6–7, with short interest at 18%.
18 October 2025
··
Rani Therapeutics (RANI) Stock Surges 150% on $1B+ Chugai Collaboration – Analysts Weigh In

Rani Therapeutics (RANI) Stock Surges 150% on $1B+ Chugai Collaboration – Analysts Weigh In

Rani Therapeutics shares surged over 150% on Oct. 17, 2025, after announcing a collaboration and license deal with Chugai Pharmaceutical worth up to $1.085 billion. The company also raised $60.3 million in PIPE financing, stating it now has funding into 2028. Trading volume spiked to 70 million shares, up from a 300,000 average. Analyst opinions remain split on the stock’s outlook.
18 October 2025
···
Beyond Meat Stock Implodes: 60% Crash After Shocking Debt-For-Equity Swap

Beyond Meat Stock Implodes: 60% Crash After Shocking Debt-For-Equity Swap

Beyond Meat shares plunged nearly 60% intraday on Oct. 13, 2025, closing at about $0.67 by Oct. 15—near record lows. The company swapped 96.9% of its 2027 convertible debt for $208.7 million in new notes and 316.15 million new shares, heavily diluting equity. Founder/CEO Ethan Brown and CFO Nandita Bakhshi resigned from the board. Analyst ratings remain strongly negative, with short interest at record highs.
18 October 2025
·
Liberty Energy (LBRT) Stock Surges 28% After Q3 Earnings – What’s Next?

Liberty Energy (LBRT) Stock Surges 28% After Q3 Earnings – What’s Next?

Liberty Energy shares surged 28% to $15.32 on Oct. 17 after Q3 results, rebounding from a prior close of $11.94. Revenue fell 17% to $947 million, with an adjusted EPS loss of $0.06, but GAAP net income reached $43 million due to one-time gains. Management raised the dividend 13%. Despite the rally, the stock remains well below last year’s $23.58 high.
18 October 2025
···
Gilead Stock Skyrockets on Patent Win and Game-Changing HIV Therapies

Gilead Stock Skyrockets on Patent Win and Game-Changing HIV Therapies

Gilead shares closed near $123 on Oct. 17, 2025, up 4.2% and close to 52-week highs, after extending Biktarvy’s U.S. exclusivity to 2036 and securing a CDC endorsement for Yeztugo. Q2 earnings beat forecasts, prompting raised guidance and analyst upgrades. Gilead is set to present positive Phase 3 Trodelvy data at ESMO and is expanding cell therapy with a $350M Interius BioTherapeutics deal.
18 October 2025
·
Gold Mania 2025: Record Rally Shatters Records – $5,000 in Sight?

Gold Mania 2025: Record Rally Shatters Records – $5,000 in Sight?

Gold prices broke $4,300 an ounce in October, up over 60% year-to-date and hitting an all-time high of $4,378 on Oct. 17. Indian festival demand pushed local premiums to decade highs, while global ETF inflows and central bank buying surged. Analysts at Metals Focus and HSBC now target $5,000/oz. Silver also set a record at $54.47/oz as bullion demand remained strong.
18 October 2025
··
Weight-Loss Drug Mania Shook Markets—Now Hims & Hers Bets on a Menopause Care Boom

Weight-Loss Drug Mania Shook Markets—Now Hims & Hers Bets on a Menopause Care Boom

Hims & Hers Health launched a menopause and perimenopause care program on its Hers platform Oct. 15, triggering a one-day stock surge of up to 16%. Shares quickly reversed, falling 11% to around $52–53 by Oct. 17. The company aims for $1 billion annual revenue in women’s health by 2026. Analysts remain divided, citing high valuation and volatile trading despite rapid revenue growth.
17 October 2025
·
Regions Financial Stock Surges on Strong Q3 Profit; Analysts Upbeat on Outlook

Regions Financial Stock Surges on Strong Q3 Profit; Analysts Upbeat on Outlook

Regions Financial shares rose about 2% on Oct. 17 after posting Q3 profit of $548 million, up 23% from a year ago, and adjusted EPS of $0.63, beating forecasts. Revenue climbed 7% to $1.9 billion. The board raised the quarterly dividend 6% to $0.265 per share. Management trimmed full-year net interest income guidance but reported improved asset quality and steady deposit growth.
17 October 2025
··
VirnetX Stock Soars 71% on Major Government Contract – What’s Next for VHC?

VirnetX Stock Soars 71% on Major Government Contract – What’s Next for VHC?

VirnetX Holding Corp’s stock surged as much as 71% on Oct. 17 after announcing a General Services Administration contract, reaching a 30-month high near $29 before settling in the low $20s by midday. The deal designates VirnetX as an approved technology provider for U.S. government agencies, expanding federal market access. Market cap rose to about $75 million. CEO Kendall Larsen called the contract a “major step forward.”
17 October 2025
··
Harrison Global Stock Surges on Bitcoin Treasury Strategy and Expansion Plans

Harrison Global Stock Surges on Bitcoin Treasury Strategy and Expansion Plans

Harrison Global Holdings shares rose about 12% to $0.22 on Oct. 17 after announcing a binding term sheet with White Lion Capital for a Bitcoin Purchase Agreement. Pre-market trading saw the stock spike to $0.23. The company also revealed plans for a ¥10 billion fund with European partners to promote Asian media content. No Wall Street analysts cover BLMZ; AI models project modest further gains.
17 October 2025
··
Achieve Life Sciences Skyrockets on FDA Boost – Is This Nicotine Addiction Breakthrough a Game Changer?

Achieve Life Sciences Skyrockets on FDA Boost – Is This Nicotine Addiction Breakthrough a Game Changer?

Achieve Life Sciences shares jumped over 20% in pre-market trading Friday after receiving an FDA Commissioner’s National Priority Voucher for its lead drug, cytisinicline. The FDA also accepted Achieve’s New Drug Application for cytisinicline as a smoking cessation treatment, with a decision expected by June 2026. ACHV stock reached multi-month highs near $3 following the news. The company’s market cap is about $160 million.
17 October 2025
··
Huntington Bancshares’ Profit Surge Defies Banking Jitters – HBAN Stock Eyes Rebound

Huntington Bancshares’ Profit Surge Defies Banking Jitters – HBAN Stock Eyes Rebound

Huntington Bancshares stock rose 2% to the mid-$15 range on Oct. 17, 2025, after Q3 net income jumped 22% to $629 million, beating estimates. Revenue reached $2.15 billion, with interest income up 11% and non-interest income up 20%. Average loans grew 9%, while net charge-offs stayed low at 0.22%. The bank is set to close its merger with Veritex Holdings on Oct. 20.
17 October 2025
·
1 … 73 74 75 76 77 … 140
Go toTop